Related Experiment Video
Updated: Nov 11, 2025
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease
Jonathan D Ravid1, Mohamed Hassan Kamel2, Vipul C Chitalia3,4,5
1School of Medicine, Boston University School of Medicine, Boston, MA, USA.
Abstract:
Chronic kidney disease (CKD) is characterized by the retention of a myriad of solutes termed uraemic (or uremic) toxins, which inflict damage to several organs, including the cardiovascular system. Uraemic toxins can induce hallmarks of cardiovascular disease (CVD), such as atherothrombosis, heart failure, dysrhythmias, vessel calcification and dysregulated angiogenesis. CVD is an important driver of mortality in patients with CKD; however, reliance on conventional approaches to managing CVD risk is insufficient in these patients, underscoring a need to target risk factors that are specific to CKD. Mounting evidence suggests that targeting uraemic toxins and/or pathways induced by uraemic toxins, including tryptophan metabolites and trimethylamine N-oxide (TMAO), can lower the risk of CVD in patients with CKD. Although tangible therapies resulting from our growing knowledge of uraemic toxicity are yet to materialize, a number of pharmacological and non-pharmacological approaches have the potential to abrogate the effects of uraemic toxins, for example, by decreasing the production of uraemic toxins, by modifying metabolic pathways induced by uraemic toxins such as those controlled by aryl hydrocarbon receptor signalling and by augmenting the clearance of uraemic toxins.
Insights
Chronic kidney disease (CKD) patients retain toxins that cause cardiovascular disease (CVD). Targeting these uremic toxins, like TMAO, may reduce CVD risk in CKD.
Area of Science:
- Nephrology
- Cardiology
- Toxicology
Background:
- Chronic kidney disease (CKD) is linked to uremic toxin accumulation.
- Uremic toxins contribute to cardiovascular disease (CVD) development in CKD patients.
- Conventional CVD risk management is inadequate for CKD patients.
Purpose of the Study:
- To review the role of uremic toxins in CKD-associated CVD.
- To explore potential therapeutic strategies targeting uremic toxins and their pathways.
Main Methods:
- Literature review of studies on uremic toxins and CVD in CKD.
- Analysis of evidence for targeting specific toxins (e.g., TMAO, tryptophan metabolites).
- Examination of potential interventions: reducing toxin production, modifying pathways, and enhancing clearance.
Main Results:
- Uremic toxins promote atherothrombosis, heart failure, and vascular calcification in CKD.
- Tryptophan metabolites and trimethylamine N-oxide (TMAO) are implicated in CKD-CVD.
- Therapeutic strategies may involve inhibiting toxin production, modulating aryl hydrocarbon receptor signaling, or increasing toxin clearance.
Conclusions:
- Targeting uremic toxins and their pathways offers a promising approach to mitigate CVD in CKD.
- Further research is needed to develop effective therapies for uremic toxicity in CKD.
- Interventions aimed at uremic toxin management are crucial for improving cardiovascular outcomes in CKD patients.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:18Chronic Kidney Disease IV: Nursing Management
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
01:22Heart Failure Drugs: Diuretics
01:24Chronic Kidney Disease II: Clinical Manifestations
01:20Acute Kidney Injury V: Interprofessional Care